Recommendation 45: We recommend antiarrhythmic drug therapy in patients with HFrEF only when symptomatic arrhythmias persist despite optimal medical therapy with guideline-directed medical therapy (GDMT), and correction of any ischemia or electrolyte and metabolic abnormalities (Strong Recommendation, Moderate Evidence).

• Only amiodarone has proven to be acceptable in the HFrEF population.